Review of commercially available biomarkers in the diagnosis of prostate cancer

Introduction Diagnosing prostate cancer is a complex process. Although PSA testing remains the basic laboratory study, new biomarkers and test are evolving quickly. Aim The aim of this review was to summarize available tests and markers for diagnosing prostate cancer. Materials and methods...

Full description

Bibliographic Details
Main Authors: Magdalena Ostrowska, Iwona Handzlik, Martyna Radomska, Adam Ostrowski
Format: Article
Language:English
Published: Kazimierz Wielki University 2022-11-01
Series:Journal of Education, Health and Sport
Subjects:
Online Access:https://apcz.umk.pl/JEHS/article/view/39667
Description
Summary:Introduction Diagnosing prostate cancer is a complex process. Although PSA testing remains the basic laboratory study, new biomarkers and test are evolving quickly. Aim The aim of this review was to summarize available tests and markers for diagnosing prostate cancer. Materials and methods Literature search was conducted using PubMed and Cohrane databases. Results and conclusions Detailed description of ExoDx, PCA3, SelectMDx, Mi-prostate Score, SChLAP1, PSA, PHI, 4K Score tests was presented. Available test ease qualification for a prostate biopsy or observation. Patients should be qualified individually in deciding on  a specific test to be performed. Urologists should be aware of each test mechanism and limitations.  
ISSN:2391-8306